Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intravenous immunoglubolin (IVIG) effect on improvement of severe pulmonary damage in COVID 19 disease

Next Previous
X
Search
Trial Profile

Intravenous immunoglubolin (IVIG) effect on improvement of severe pulmonary damage in COVID 19 disease

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Immune globulin (Primary)
  • Indications COVID 2019 infections; Pulmonary fibrosis
  • Focus Therapeutic Use

    • Most Recent Events

    • 03 Aug 2020 Form of drug has been assumed from RDI. and also as no term available for pulmonary damage, have added pulmonary fibrosis, similar term for this.
    • 03 Aug 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top